ARCHIVES

Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

Page 2: The Debate Over Brigham’s Containment Bag Study

November 21, 2014

In Brief: NCHSR Says Autologous Marrow Transplant Is A “Reasonable Therapeutic Alternative”

August 11, 1989

Case Western Wins Renewal.

October 5, 2001

R01 Grants Pool, New Investigators Hit By Budget Strains

October 27, 1989

NCI Plans $30 Million In Patient-Oriented Chemoprevention research In Next 5 Years

December 6, 1996

In Brief: NIH Budget Cut Being Considered, Threatening NCI’s Plan For Reaching Year 2000 Goals

December 13, 1984